NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
Motivation from Failure
Imagine the following scenario: Your patient presents for a routine follow-up appointment. As you review the chart you realize the labs, blood pressure, and/or weight…
Statins and Brain Fog: Confusing for Patients, Prescribers, and Me
HMG-CoA reductase inhibitors (statins) were FDA-approved in 1987 and their introduction has revolutionized lipid and cardiovascular (CV) management for the past three decades. Despite this,…
Elevated and Dysfunctional HDL
High density lipoprotein (HDL) has long been known as a negative risk factor for the development of atherosclerosis and cardiovascular disease. The traditional explanation of…
Icosapent Ethyl-Treated Hypertriglyceridemia to Reduce ASCVD Residual Risk
The Reduction of Cardiovascular Events with Icosapent Ethyl Intervention Trial (REDUCE-IT) as authored by Bhatt, DL et al, shows strong evidence that icosapent ethyl, in…
The Unique South Asian Phenotype and Opportunities for Early Intervention to Prevent Diabetes and ASCVD
There are close to 4 million SAs living in North America (2.84 million in the US). Lipid abnormalities in SAs are closely intertwined with insulin…
Genetic Testing in Dyslipidemia
S1E2: General Gaps in FH Care
Dr. Alan Browns sits down with Dr. David Davidson to provide insight into the gaps in treatment of patients with Familial Hypercholesterolemia.
Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association
Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association
